174 related articles for article (PubMed ID: 32802527)
41. [The clinical patterns and RET proto-oncogene in fifteen multiple endocrine neoplasia type 2A pedigrees].
Zhou YL; Zhu SX; Li JJ; Liu JB; Yin M; Xiao BY; Yu CL; Wang LM; Gu LQ; Cui B; Ning G; Li XY; Zhao YJ
Zhonghua Nei Ke Za Zhi; 2007 Jun; 46(6):466-70. PubMed ID: 17663821
[TBL] [Abstract][Full Text] [Related]
42. Guidelines for diagnosis and therapy of MEN type 1 and type 2.
Brandi ML; Gagel RF; Angeli A; Bilezikian JP; Beck-Peccoz P; Bordi C; Conte-Devolx B; Falchetti A; Gheri RG; Libroia A; Lips CJ; Lombardi G; Mannelli M; Pacini F; Ponder BA; Raue F; Skogseid B; Tamburrano G; Thakker RV; Thompson NW; Tomassetti P; Tonelli F; Wells SA; Marx SJ
J Clin Endocrinol Metab; 2001 Dec; 86(12):5658-71. PubMed ID: 11739416
[TBL] [Abstract][Full Text] [Related]
43. Characterization of ret oncogenic activation in MEN2 inherited cancer syndromes.
Xing S; Smanik PA; Oglesbee MJ; Trosko JE; Mazzaferri EL; Jhiang SM
Endocrinology; 1996 May; 137(5):1512-9. PubMed ID: 8612479
[TBL] [Abstract][Full Text] [Related]
44. A 6-Base Pair in Frame Germline Deletion in Exon 7 Of RET Leads to Increased RET Phosphorylation, ERK Activation, and MEN2A.
Latteyer S; Klein-Hitpass L; Khandanpour C; Zwanziger D; Poeppel TD; Schmid KW; Führer D; Moeller LC
J Clin Endocrinol Metab; 2016 Mar; 101(3):1016-22. PubMed ID: 26765577
[TBL] [Abstract][Full Text] [Related]
45. Unusual presentation of multiple endocrine neoplasia type 2A in a patient with the C634R mutation of the RET-protooncogene.
Harzallah F; Barlier A; Feki M; Enjalbert A; Slimane H
Ann Endocrinol (Paris); 2008 Dec; 69(6):523-5. PubMed ID: 18752792
[TBL] [Abstract][Full Text] [Related]
46. Identification of tyrosine residues that are essential for transforming activity of the ret proto-oncogene with MEN2A or MEN2B mutation.
Iwashita T; Asai N; Murakami H; Matsuyama M; Takahashi M
Oncogene; 1996 Feb; 12(3):481-7. PubMed ID: 8637703
[TBL] [Abstract][Full Text] [Related]
47. Diagnostic correlation between RET proto-oncogene mutation, imaging techniques, biochemical markers and morphological examination in MEN2A syndrome: case report and literature review.
Sovrea AS; Dronca E; Galatâr M; Radian S; Vornicescu C; Georgescu C
Rom J Morphol Embryol; 2014; 55(2):389-400. PubMed ID: 24969991
[TBL] [Abstract][Full Text] [Related]
48. Medullary Thyroid Carcinoma With Exon 2 p.L56M RET Variant: Clinical Particular Features in Two Patients.
Paragliola RM; Lovicu RM; Papi G; Capoluongo E; Minucci A; Canu G; Pontecorvi A; Corsello SM
Front Endocrinol (Lausanne); 2018; 9():398. PubMed ID: 30072953
[TBL] [Abstract][Full Text] [Related]
49. Analysis of the RET proto-oncogene in sporadic parathyroid adenomas.
Williams GH; Rooney S; Carss A; Cummins G; Thomas GA; Williams ED
J Pathol; 1996 Oct; 180(2):138-41. PubMed ID: 8976870
[TBL] [Abstract][Full Text] [Related]
50. Molecular Screening for RET Proto-Oncogene Mutations in a German MEN2A Pedigree.
Wundrack I; Reichert J; Langer HJ; Leicht E; Herrmann M; Subke F; Meese E; Blin N
Endocr Pathol; 1996; 7(1):71-76. PubMed ID: 12114682
[TBL] [Abstract][Full Text] [Related]
51. Adrenal ganglioneuromas in children with multiple endocrine neoplasia type 2: a report of two cases.
Lora MS; Waguespack SG; Moley JF; Walvoord EC
J Clin Endocrinol Metab; 2005 Jul; 90(7):4383-7. PubMed ID: 15827098
[TBL] [Abstract][Full Text] [Related]
52. Hereditary medullary thyroid carcinoma syndromes: experience from western India.
Diwaker C; Sarathi V; Jaiswal SK; Shah R; Deshmukh A; Thomas AE; Prakash G; Malhotra G; Patil V; Lila A; Shah N; Bandgar T
Fam Cancer; 2021 Jul; 20(3):241-251. PubMed ID: 33392850
[TBL] [Abstract][Full Text] [Related]
53. Multiple endocrine neoplasia syndromes, children, Hirschsprung's disease and RET.
Moore SW; Zaahl MG
Pediatr Surg Int; 2008 May; 24(5):521-30. PubMed ID: 18365214
[TBL] [Abstract][Full Text] [Related]
54. [The treatment of medullary thyroid cancer].
Fujita T; Fujimori M
Gan To Kagaku Ryoho; 2009 Oct; 36(10):1627-31. PubMed ID: 19838021
[TBL] [Abstract][Full Text] [Related]
55. RET activation by germline MEN2A and MEN2B mutations.
Borrello MG; Smith DP; Pasini B; Bongarzone I; Greco A; Lorenzo MJ; Arighi E; Miranda C; Eng C; Alberti L
Oncogene; 1995 Dec; 11(11):2419-27. PubMed ID: 8570194
[TBL] [Abstract][Full Text] [Related]
56. Prophylactic thyroidectomy for medullary thyroid carcinoma in gene carriers of MEN2 syndrome.
Lallier M; St-Vil D; Giroux M; Huot C; Gaboury L; Oligny L; Desjardins JG
J Pediatr Surg; 1998 Jun; 33(6):846-8. PubMed ID: 9660211
[TBL] [Abstract][Full Text] [Related]
57. Co-segregation of MEN2 and Hirschsprung's disease: the same mutation of RET with both gain and loss-of-function?
Takahashi M; Iwashita T; Santoro M; Lyonnet S; Lenoir GM; Billaud M
Hum Mutat; 1999; 13(4):331-6. PubMed ID: 10220148
[TBL] [Abstract][Full Text] [Related]
58. Characterization of gene expression induced by RET with MEN2A or MEN2B mutation.
Watanabe T; Ichihara M; Hashimoto M; Shimono K; Shimoyama Y; Nagasaka T; Murakumo Y; Murakami H; Sugiura H; Iwata H; Ishiguro N; Takahashi M
Am J Pathol; 2002 Jul; 161(1):249-56. PubMed ID: 12107109
[TBL] [Abstract][Full Text] [Related]
59. Long-term Clinicopathological Features of a Family with Multiple Endocrine Neoplasia Type 2A Caused by C634R
Prabhu M; Shakya S; Ballal S; Shamim SA; Bal C
Indian J Nucl Med; 2020; 35(1):48-53. PubMed ID: 31949369
[TBL] [Abstract][Full Text] [Related]
60. Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma.
Schulten HJ; Al-Maghrabi J; Al-Ghamdi K; Salama S; Al-Muhayawi S; Chaudhary A; Hamour O; Abuzenadah A; Gari M; Al-Qahtani M
Anticancer Res; 2011 Dec; 31(12):4179-83. PubMed ID: 22199277
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
